INTRODUCTION
============

Acute respiratory failure (ARF) is a common cause of admission to the intensive care unit (ICU) that occurs for several reasons, including pulmonary disease, neuromuscular disease, shock and the need for airway protection or temporary respiratory support after major surgery. For patients with ARF, mechanical ventilation (MV) is the cornerstone of management [@b1-cln_71p145],[@b2-cln_71p145]. Patients admitted to ICUs who need MV are expected to have higher mortality rates compared with those who do not require respiratory support [@b3-cln_71p145].

Despite advances in the management of ARF with MV, mortality has not decreased significantly and costs remain high [@b4-cln_71p145][@b5-cln_71p145][@b6-cln_71p145][@b7-cln_71p145][@b8-cln_71p145][@b9-cln_71p145]. Knowledge of the epidemiology of patients requiring MV, including mortality rates and mortality risk factors, may help to improve therapeutic strategies, as might counseling of patients or their relatives [@b10-cln_71p145]. Esteban et al. found that mortality depends on (i) factors present at the start of MV, (ii) factors developed during the course of MV, and (iii) factors related to patients\' management [@b10-cln_71p145]. Other studies have addressed the specific risk factors in such patients, including multiple organ dysfunction, age, the Simplified Acute Physiology Score II (SAPS II), nonpulmonary sources of respiratory failure, and immunosuppression [@b3-cln_71p145],[@b5-cln_71p145],.

Knowledge of the epidemiological profile of patients with ARF requiring MV in Latin America is scarce, particularly in Brazil. In particular, Tomicic et al. [@b14-cln_71p145] explored the characteristics and mortality risk factors of 156 patients who required MV in 19 ICUs in Chile, and Azevedo et al. [@b15-cln_71p145] evaluated 773 adult patients admitted to 45 ICUs in Brazil over a two-month period who required MV for more than 24 hours. Further studies are needed to improve the understanding of patients who require MV in developing countries in which there is limited resource allocation. Therefore, our study aimed to determine the characteristics, the frequency and the mortality rates of patients who needed MV in southern Brazil.

MATERIALS AND METHODS
=====================

Study design
------------

This prospective cohort study was conducted between March 1^st^, 2004 and April 30^th^, 2007, in the ICU of the Hospital de Clínicas de Porto Alegre, a teaching hospital in the city of Porto Alegre, in southern Brazil. In Porto Alegre and its metropolitan area, the estimated population size is 1,436,123 and 4,063,886 inhabitants, respectively.

The ICU has 24 beds and is assisted by one doctor and nurse assistant for every five patients and by one nurse technician for every two patients during the day. In addition, one physiotherapist and one medical resident aid every ten and two patients, respectively. During the night and on weekends, one doctor and nurse assistant help every ten patients, one nurse technician helps every two patients, and one medical resident helps every ten patients. At the time of the study, the ICU occupancy rate was 90%.

Data collection
---------------

Patients admitted to the ICU who were ≥18 years old were included in the study after completing 24 consecutive hours on either non-invasive MV (NIMV) or invasive MV (IMV). Patients were excluded if they did not complete 24 hours on MV or did not require it. Each patient was followed during the course of MV for a period of 28 days or until death. All information was collected by trained personnel through a standardized questionnaire.

Study variables
---------------

The following information was obtained:

### Outcome variables

\(i\) the overall mortality rate, defined as the mortality rate of all patients admitted to the ICU during the period of the study; (ii) the specific mortality rate, defined as the total number of deaths among MV patients during the study period; and (iii) the length of stay (LOS) in the ICU and hospital.

### Independent variables

Age; gender; the Acute Physiology and Chronic Health Evaluation II (APACHE II) score obtained within the first 24 hours of admission; patient status (clinical or surgical); the modality of respiratory support (NIMV or IMV); the main reason(s) for MV; tracheostomy; and previous health status, including hepatic, renal, cardiovascular, neurological, gastrointestinal and hematologic failure [@b16-cln_71p145]. Data were collected regarding events that developed during the MV period, including acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) [@b17-cln_71p145]; barotrauma; sepsis; ventilator-acquired pneumonia (VAP) [@b18-cln_71p145]; organ failure [@b16-cln_71p145]; weaning failure; and use of drugs such as sedatives, analgesics, and vasoactive or neuromuscular blockers. Weaning failure was defined as a need for reintubation and IMV within the first 48 hours after extubation. Data on arterial blood gases, chest X-rays, ventilatory parameters and modes of MV were also recorded.

Statistical analysis
--------------------

Data analysis was performed considering factors present at the start and/or occurring over the course of MV. Categorical variables were coded as dummy variables to compare all categories with the one having the lower mortality. A univariate analysis was performed to identify the variables associated with mortality using either the chi-squared (χ^2^) test (categorical variables) or Student\'s *t* test (continuous variables). Continuous variables were also compared using ANOVA and the *post hoc* Tukey test. A χ^2^ test for linear trends was used to relate mortality rates to the number of organ failures. A Kaplan-Meier analysis was used to determine the probability of survival during MV. A Cox proportional hazards model was conducted using the PHREG procedure from SAS to identify factors independently associated with mortality. In this analysis, the outcome was defined as the time, in days, between the beginning of MV and death. The criteria for variables entering the multivariable model was *p*\<0.25 in the univariable models and/or clinical relevance. Variables were excluded from the model one at a time, keeping those significant at 5% in the final model. The statistical analysis was performed using SPSS® version 18.0 and SAS® version 9.2. The analysis was reviewed by a consultant with formal statistical training and experience. His analysis was performed after all data collection and after the analysis had been independently carried out by another investigator.

Ethics
------

The study was approved by the hospital\'s research ethics committee (number: 03-502) with an informed consent waiver. The research team also signed an institutional document ensuring full confidentiality of the patients\' records.

RESULTS
=======

A total of 2,430 patients were admitted to the ICU during the study period, and 1,115 (46%) were included in the study.

[Table 1](#t1-cln_71p145){ref-type="table"} describes the characteristics of the studied population. The most common reasons for initiation of MV were sepsis (41.8%), shock (37.8%), pneumonia (37%) and ALI/ARDS (15%). The frequency of IMV was 97.7%, which included patients who started on this mode of ventilation at the beginning of the study (92.6%) and those who failed NIMV (5.1%). The rate of weaning failure for IMV was 29.4%.

Regarding NIMV, 7.4% (n=83) patients initiated this mode of ventilatory support, but only 2.3% (n=26) remained on NIMV during the entire course of MV. Therefore, the failure rate of NIMV was 68.7%. The major reasons for the use of NIMV were pneumonia (49%; n=41), sepsis (31%; n=26), ALI/ARDS (17%; n=14), and chronic obstructive pulmonary disease (COPD) (15%; n=13). The rate of NIMV failure was 79% in ALI/ARDS, 61.5% in pneumonia, 73% in sepsis, and 38.5% in COPD. Additionally, 10.4% of the patients needed tracheostomy and 70.1% (782/1115) needed vasopressors.

The ventilator modes and the monitored respiratory variables on days 1, 2 and 3 (mean values) of IMV in all patients as well as in the COPD and ARDS groups in particular are presented in [Table 2](#t2-cln_71p145){ref-type="table"}. Assisted/controlled pressure ventilation was the most commonly used mode of IMV in all groups. [Table 3](#t3-cln_71p145){ref-type="table"} describes the outcomes among the COPD, ARDS and other patient (non-COPD and non-ARDS) groups. Patients with ARDS presented a longer duration of IMV compared with those with COPD and other patients (12.1±8.7 *vs*. 8.9±5.5 and 9.3±7.3, *p*=0.01). The LOS values in the ICU and hospital were similar among groups.

The overall and the specific mortality rates of MV patients were 23% (564/2430) and 51% (564/1115), respectively. Regarding COPD patients in particular, the mortality rate was 26.7% (16/60). In ARDS patients, the mortality rate was 66% (204/307). The mortality rate in patients who developed ARDS during MV (71%; 126/180) was higher, but not significantly different (*p*=0.15), compared with the rate in those with ARDS as the cause of MV (63%; 78/127). [Figure 1](#f1-cln_71p145){ref-type="fig"} presents the survival curves for the ARDS and COPD groups and also for the other studied patients (*p*\<0.001).

The main events that occurred during MV were sepsis (n=210; 18.8%), VAP (n=181; 16%), ARDS (n=180; 16%), and barotrauma (n=32; 2.8%). The mortality rates are shown in [Table 4](#t4-cln_71p145){ref-type="table"}; these rates increased as the number of failing organs increased. There was a high percentage of patients with failure of three or more organs in the cohort (45%), especially among patients with ARDS (52%) and in COPD patients (15%). In addition, patients developed the following types of organ failure during the course of MV: renal (n=290; 26%), cardiovascular (n=227; 20.4%), coagulopathic (n=201; 18%), neurological (n=115; 10%) and hepatic (n=86; 7.7%).

The factors independently associated with hospital mortality are illustrated in [Table 5](#t5-cln_71p145){ref-type="table"}. The conditions present at the beginning of MV were age; the APACHE II score; renal and neurological failure; and, as causes of MV, ALI/ARDS and sepsis. The conditions occurring over the course of MV were ALI/ARDS; sepsis; and renal, cardiovascular, and hepatic failure. The following variables were negatively associated with mortality: COPD exacerbation and pneumonia as causes of MV, in addition to VAP.

DISCUSSION
==========

The main findings of our study were as follows: (i) the hospital mortality rate of patients who required MV was 51% and (ii) the factors associated with increased mortality included conditions present at the start of MV as well as conditions that occurred during mechanical support.

The frequency of MV in our study was in agreement with frequencies described in other publications [@b3-cln_71p145],[@b11-cln_71p145]. Carson et al. showed that the incidence of MV increased by 11% over 7 years, with a higher burden of comorbidities and fewer discharges to home [@b8-cln_71p145]. Additionally, assisted/controlled pressure ventilation was the most commonly used mode of IMV in all groups in the current study and this observation was similar to the results of another study [@b10-cln_71p145].

The rate of mortality in the present study was higher than rates in several multicenter prospective cohort studies, which ranged from 30.7-42% [@b5-cln_71p145],[@b8-cln_71p145],[@b10-cln_71p145],[@b11-cln_71p145],[@b14-cln_71p145],[@b15-cln_71p145],[@b19-cln_71p145]. In one Brazilian multicenter study by Azevedo et al., the hospital mortality rate was 42% [@b15-cln_71p145]. When comparing the mortality rates in our study with those in the literature, several aspects must be taken into account. These aspects include different methodologies (e.g., inclusion criteria, characteristics of the population) and different severities of illness. Our study specifically showed that APACHE II score, organ failures, ALI/ARDS, sepsis and age were independently associated with hospital mortality. Mortality risk factors have also been the focus of several investigations [@b3-cln_71p145],[@b5-cln_71p145],[@b8-cln_71p145],[@b10-cln_71p145],[@b11-cln_71p145],. The high severity of illness in our cohort may have contributed to the elevated mortality rates. In this study, the mean APACHE II score was higher when compared with scores in other studies [@b5-cln_71p145],[@b14-cln_71p145]. Studies have also evaluated the severity of illness using the SAPS II score, which is difficult to compare across studies [@b10-cln_71p145],[@b11-cln_71p145],[@b15-cln_71p145]. Further evidence that our population had more severe illness was the higher percentage of patients with failure of three or more organs (45%) compared with the percentage in another study, in which 13% of the patients had this condition [@b13-cln_71p145]. Other reasons for higher mortality in our study were the reasons for initiation of MV, which included sepsis (41.8%), shock (37.8%), pneumonia (37%) and ALI/ARDS (15%). Azevedo et al. showed that the main causes included pneumonia (27%), neurological failure (19%) and non-pulmonary sepsis (12%) [@b15-cln_71p145]. In addition, Esteban et al. reported different percentages for the main causes of MV, such as postoperative patients [@b10-cln_71p145]. Taken together, these disparities probably resulted in a less severely ill population with lower mortality rates [@b10-cln_71p145],[@b15-cln_71p145].

The mortality of ARDS patients observed in our study was high. One reason for this high mortality rate in ARDS patients was the severity of illness, with a mean APACHE II score of 23.6. Furthermore, 42.5% of ARDS patients had failure of three or more organs. Additionally, in ARDS patients, the tidal volumes were higher than those suggested in the context of a lung-protective strategy, which reduces mortality in these patients [@b20-cln_71p145]. During the period of our study, a lung-protective strategy was not completely incorporated into our practice, which also could have affected the mortality rate. Another reason for discrepancy could be that in our study, we used a previously established criterion for the classification of ALI/ARDS [@b17-cln_71p145], whereas mortality rates in other studies may have been influenced by the recent new Berlin definition of this syndrome [@b21-cln_71p145]. In Brazil in particular, using the Berlin definition, Azevedo et al. reported a hospital mortality rate of 52% [@b15-cln_71p145]. A systematic review found that ARDS mortality has remained static, at 44%, for observational studies since the 1994 consensus definition of this syndrome [@b22-cln_71p145],[@b23-cln_71p145]. For example, in the ALIEN study, the hospital mortality rate was 47.8% [@b24-cln_71p145]. In the setting of low-to-middle countries, best-practices strategies should be employed to reduce the mortality rates in ARDS patients.

Our finding that age was independently associated with mortality in MV patients has also been described in previous studies [@b8-cln_71p145]. In our study, COPD and pneumonia as causes of MV, in addition to VAP, were found to be negatively associated with mortality in these patients. COPD was also found to be protective by Esteban et al. [@b10-cln_71p145]. One possible explanation for the negative association of COPD and hospital mortality in the present study may be that such patients were less severely ill than those without COPD were; these patients presented fewer morbidities during the MV period (nonrespiratory system dysfunction). It should be noted that few patients had COPD exacerbation as a cause of MV and admission to the ICU in this study. Pneumonia as a cause of MV was also found to be negatively related to mortality, which may have been due to a lower percentage of failure of three or more organs in this group of patients. In two studies that examined risk factors for needing ventilatory support, pneumonia was not associated with mortality after the multivariate analysis [@b6-cln_71p145],[@b10-cln_71p145]. Studies of fatality rates comparing patients with and without VAP have generated contradictory results as to whether this condition increases mortality [@b10-cln_71p145],. It should be noted that the present study was not designed to examine only VAP patients, but rather included a myriad of patients requiring MV. In addition, according to our analysis, VAP patients had a lower percentage of organ failure and of sepsis as a cause of MV compared with patients without VAP.

Our study showed a lower frequency of NIMV compared with IMV. Only 2.3% of patients remained on NIMV during the entire course of MV, which could be explained by our overwhelming patient demand for the ICU; in fact, many patients who needed NIMV remained in the emergency department or in the hospital ward. Our percentage of NIMV use was lower compared with percentages in other studies [@b15-cln_71p145],[@b19-cln_71p145],[@b28-cln_71p145],[@b29-cln_71p145]. For example, a recent Brazilian study had higher percentage of NIMV patients, which could have led to different outcomes [@b15-cln_71p145]. Additionally, the percentage of NIMV failure was higher in our study than in recent investigations [@b15-cln_71p145],[@b19-cln_71p145],[@b29-cln_71p145], which may have been related to the difference in the severity of illness of the patients between the studies. More specifically, there was an important difference in the main reasons for the use of NIMV. Our study also found a higher percentage of patients with pneumonia, sepsis and ALI/ARDS and a small number of patients with a greater demonstrated benefit regarding COPD exacerbation and acute pulmonary edema [@b29-cln_71p145][@b30-cln_71p145][@b31-cln_71p145].

The percentage of weaning failure in the present study was higher (29.4%) compared with percentages in the literature (5-20%) [@b15-cln_71p145],[@b32-cln_71p145]. Possible reasons may be related to (i) the fact that certain patients at high risk of weaning failure could not have used NIMV immediately after extubation and (ii) the lack of a weaning protocol. Although recognizing that a protocol would not necessarily be crucial, we think that it could have helped, considering that our ICU is a multidisciplinary unit with a heterogeneous patient population. Within the last few years, we have been using a weaning protocol including NIMV in high-risk patients, sharper surveillance regarding sedation, and physiotherapist participation in patients\' weaning process. Indeed, recent data have shown that our percentage of weaning failure has dropped to 21% [@b32-cln_71p145].

The limitations of our study include that (i) the data were obtained from one ICU, so the results may not be generalizable to other patients who require MV; (ii) the ICU was at a tertiary university hospital that admits patients with more severe illness/conditions, so the interpretation of the results may be different from that in other studies whose patients did not have similar disease severity; and (iii) comorbidities, such as neoplasia, AIDS, cirrhosis, and chronic renal failure, were not studied, so the influence of such conditions on the mortality rates of the studied population could not be estimated. Taking into account these limitations, to the best of our knowledge, this large study best describes the factors associated with mortality in ICU patients who required MV.

The hospital mortality rate of MV patients in our study was higher than rates reported in the literature, which may have been related to the severity of illness of the studied population. Furthermore, the factors associated with increased mortality included conditions present at the beginning of MV as well as conditions that occurred during mechanical support. The epidemiological aspects of MV patients explored in our investigation could enhance knowledge of such patients in South America. To the best of our knowledge, this large cohort study of MV patients on this continent may contribute to a more global understanding regarding the use of MV. In developing countries such as Brazil in particular, the limited availability of ICU beds results in the admission of patients with more severe illness, which may account for the higher mortality rates. These observations should be considered when comparing the mortality of such patients among countries under diverse socioeconomic conditions.
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![**Figure 1.** Kaplan-Meier curves of the probability of survival over time for mechanical ventilation.](cln-71-03-145-g001){#f1-cln_71p145}

###### 

Characteristics of the Studied Patients on Admission to the Intensive Care Unit.

  Characteristic                                           Number of Patients Mechanically Ventilated
  -------------------------------------------------------- --------------------------------------------
  Age, median±SD                                           57.2±18
  Gender, males                                            582 (52%)
  APACHE II score, mean±SD                                 22.6±8.3
  Medical/Surgical                                         771 (69%)/344 (31%)
  Source of admission                                      
      Hospital ward                                        625 (56%)
      Emergency department                                 278 (25%)
      Other hospitals                                      212 (19%)
  Reason for the initiation of mechanical ventilation^1^   
      Sepsis                                               466 (41.8%)
      Shock                                                421 (37.8%)
      Pneumonia                                            415 (37%)
      ALI                                                  167 (15%)
          ALI without ARDS                                 40 (3.6%)
          ARDS                                             127 (11.4%)
      Neurological condition                               
          Stroke                                           79 (7.1%)
          Neuromuscular disease                            15 (1.3%)
          Other neurological condition                     32 (3%)
      COPD                                                 60 (5.4%)
      Cardiac arrest                                       67 (6.0%)
      Asthma                                               16 (1.6%)
      Other                                                14 (1.2%)

APACHE II = Acute Physiology and Chronic Health Evaluation II; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; SD = standard deviation; ^1^ more than one reason for initiation of mechanical ventilation was allowed.

###### 

Ventilator Modes and Monitored Variables on Days 1, 2 and 3 (Mean Values) of Invasive Mechanical Ventilation.

                                      Overall (n=976)^1^   COPD (n=56)^a^   ARDS (n=263)^a^
  ----------------------------------- -------------------- ---------------- -----------------
  Ventilator mode, no. (%)                                                  
      ACP                             715 (73)             37 (66)          200 (76)
      PSV                             195 (20)             14 (25)          46 (17.5)
      CPAP                            29 (3)               3 (5)            9 (3.5)
      ACV                             22 (2.5)             2 (4)            7 (2.5)
      SIMV                            15 (1.5)             0 (0)            7 (2.5)
  Monitored variable, mean±SD                                               
      Peak pressure, cm H~2~O         25.5±8.1             24±4.8           28.5±8.2
      Plateau pressure, cm H~2~O      21.5±5.8             20.2±4.6         23.6±6.4
      Tidal volume, ml/kg (PBW)       10.5±3.3             10±3             9±3.3
      Respiratory rate, breaths/min   20.1±4.1             19.3±3.8         21.2±4.4
      PaO~2~/FiO~2~                   298.8±155            292.4±118        169±111.3
      PEEP, cm H~2~O                  6.6±2.5              5.8±1.5          9±4

COPD = chronic obstructive pulmonary disease; ARDS = acute respiratory distress syndrome; ACP = assisted/controlled pressure ventilation; ACV = assisted/controlled volume ventilation; PSV = pressure support ventilation; CPAP = continuous positive airway pressure; SIMV = synchronized intermittent mandatory ventilation; PBW = predicted body weight; PEEP = positive end-expiratory pressure; SD = standard deviation; ^1^ the percentages of missing data for all patients and for the COPD and ARDS groups in particular were 12%, 11%, and 14%, respectively; ^2^ refers to non-COPD and non-ARDS patients.

###### 

Duration of Mechanical Ventilation and Length of Stay in the Intensive Care Unit and in the Hospital in the Studied Patients.

                                                              Other Patients[2](#tfn5-cln_71p145){ref-type="table-fn"} (n=748)   COPD (n=60)   ARDS (n=307)   *p*-value[\*](#tfn6-cln_71p145){ref-type="table-fn"}
  ----------------------------------------------------------- ------------------------------------------------------------------ ------------- -------------- ------------------------------------------------------
  Duration of MV[1](#tfn4-cln_71p145){ref-type="table-fn"}    9.3±7.3                                                            8.9±5.5       12.1±8.7       \<0.01[\*\*](#tfn7-cln_71p145){ref-type="table-fn"}
  LOS in ICU[1](#tfn4-cln_71p145){ref-type="table-fn"}        14.6±11.5                                                          14.3±10       15.6±11.6      0.19
  LOS in hospital[1](#tfn4-cln_71p145){ref-type="table-fn"}   24.7±22.9                                                          24.3±18.1     22.3±21        0.12

MV = mechanical ventilation; LOS = length of stay; COPD = chronic obstructive pulmonary disease; ARDS = acute respiratory distress syndrome;

days;

refers to non-COPD and non-ARDS patients;

**\<?ENTCHAR ast?\>:** *p*-value for ANOVA;

**\<?ENTCHAR ast?\>\<?ENTCHAR ast?\>:** *p*\<0.001 for ANOVA (and *p*\<0.05 for the Tukey test for the following comparisons: COPD *vs*. ARDS patients and other patients *vs*. ARDS patients).

###### 

Severity of Illness and Hospital Mortality According to the Number of Organs with Failure.

  Group   n     Age[\*](#tfn9-cln_71p145){ref-type="table-fn"}   APACHE II Score[\*](#tfn9-cln_71p145){ref-type="table-fn"}   Hospital Mortality (%)[\*\*](#tfn10-cln_71p145){ref-type="table-fn"}   HR (95% CI)[\*\*](#tfn10-cln_71p145){ref-type="table-fn"}
  ------- ----- ------------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------------- -----------------------------------------------------------
  ARF+0   138   57.5±17.8                                        19.0±7.2                                                     21.0%                                                                  1.0
  ARF+1   248   57.1±19.2                                        19.9±7.4                                                     37.1%                                                                  1.91 (1.26-2.89)
  ARF+2   285   58.7±17.3                                        22.7±7.6                                                     54.4%                                                                  3.35 (2.26-4.99)
  ARF+3   249   58.5±17.3                                        24.9±8.4                                                     64.7%                                                                  4.19 (2.82-6.23)
  ARF+4   139   54.0±17.5                                        26.6±9.2                                                     69.8%                                                                  4.62 (3.05-6.99)
  ARF+5   56    52.4±19.9                                        25.3±7.3                                                     73.2%                                                                  5.24 (3.25-8.43)

APACHE II = Acute Physiology and Chronic Health Evaluation II; ARF = acute respiratory failure; HR = hazard ratio; CI = confidence interval;

**\<?ENTCHAR ast?\>:** mean±standard deviation;

**\<?ENTCHAR ast?\>\<?ENTCHAR ast?\>:** *p*-value for linear trend: hospital mortality (*p*\<0.001) and HR (*p*\<0.001).

###### 

Statistical Analysis of the Factors Associated with Mortality in Mechanical Ventilation Patients.

  Variable                         Univariable                     Multivariable        
  -------------------------------- -------------------- ---------- -------------------- ---------
  Age (years)                      1.07 (1.002-1.012)   0.004      1.01 (1.004-1.014)   \<0.001
  APACHE II score                  1.01 (1.007-1.02)    \<0.0001   1.01 (1.002-1.014)   \<0.005
  Chronic use of corticosteroids   0.72 (0.53-0.97)     0.03                            
  Failure previous to MV                                                                
  Cardiovascular                   1.42 (1.20-1.67)     \<0.0001                        
  Coagulopathic                    1.46 (1.21-1.77)     \<0.0001                        
      Hepatic                      1.26 (1.02-1.57)     0.03                            
      Renal                        1.34 (1.14-1.59)     0.0005     1.29 (1.06-1.56)     0.011
  Neurological                     1.13 (0.94-1.35)     0.17       1.25 (1.031.52)      0.024
  Cause of MV initiation                                                                
      COPD                         0.42 (0.25-0.69)     0.0006     0.58 (0.35-0.98)     0.042
      ALI/ARDS                     1.33 (1.08-1.65)     0.008      1.38 (1.08-1.77)     0.009
      Sepsis                       1.47 (1.25-1.73)     \<0.0001   1.33 (1.10-1.61)     0.003
      Pneumonia                    0.88 (0.74-1.05)     0.15       0.78 (0.65-0.95)     0.013
      Asthma                       0.43 (0.16-1.15)     0.09                            
  Condition occurring during MV                                                         
      Sepsis                       1.48 (1.22-1.79)     \<0.0001   1.53 (1.23-1.90)     \<0.001
      VAP                          0.70 (0.53-0.91)     0.009      0.62 (0.46-0.83)     0.001
      ALI/ARDS                     1.42 (1.19-1.71)     0.0001     1.31 (1.07-1.61)     \<0.010
      Failure                                                                           
  Cardiovascular                   1.54 (1.28-1.85)     \<0.0001   1.32 (1.07-1.62)     ≤0.009
  Coagulopathic                    1.41 (1.16-1.72)     0.0006                          
      Hepatic                      1.91 (1.48-2.48)     \<0.0001   1.67 (1.26-2.21)     ≤0.001
      Renal                        1.86 (1.57-2.22)     \<0.0001   1.75 (1.42-2.15)     \<0.001

ALI/ARDS = acute lung injury/acute respiratory distress syndrome; APACHE II = Acute Physiology and Chronic Health Evaluation II; COPD = chronic obstructive pulmonary disease; MV = mechanical ventilation; VAP= ventilator-associated pneumonia;

**\<?ENTCHAR ast?\>:** hazard ratio (HR) and 95% confidence interval (CI) for the HR;

**\<?ENTCHAR ast?\>\<?ENTCHAR ast?\>:** *p*-value for the analysis. In the final multivariate model, variables with *p*\>0.05 were not included.
